Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 P50 suppression amplitudes of S1, S2, and S1/S2 and latencies at different time points

From: Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study

 

TD (n = 31)

TSC (n = 7)

Time point

D0

D0

D91

D119

Trial

Mean amplitude (SD)

Mean amplitude (SD)

S1 amplitude

1.65 (1.01)

1.42 (.68)

1.98 (1.26)

1.67 (1.38)

S1 latency

61.35 (10.39)

62.67 (11.40)

63.33 (9.06)

62.67 (9.95)

S2 amplitude

1.00 (1.04)

.88 (.70)

1.02 (.89)

.74 (.52)

S2 latency

59.27 (15.45)

65 (9.97)

67.75 (14.44)

66.22 (14.12)

S1/S2 ratio

.58 (.55)

.73 (.50)

.81 (.85)

.65 (.52)

  1. Abbreviations: TD typically developing controls, TSC tuberous sclerosis complex
Back to article page

Molecular Autism

ISSN: 2040-2392